Canada halts AstraZeneca COVID-19 vaccine for people 55 and under, citing 'uncertainty' on blood clots


Canada's 13 provinces and territories, on advice from the National Advisory Committee on Immunization, suspended use of AstraZeneca's vaccine on people 55 and younger Monday. The advisory committee said its recommendation was a "precautionary measure" due to "rare" cases of blood clots in Europe, mostly affecting women under 55. "There is substantial uncertainty about the benefit of providing AstraZeneca COVID-19 vaccines to adults under 55 given the potential risks," said Dr. Shelley Deeks, the committee's vice chair.
AstraZeneca is a relatively small part of Canada's COVID-19 vaccine strategy, but it is hugely important for the global vaccination effort and is widely used in Britain. Europe's drug regulator said there is no evidence of an overall increase in blood clots and the vaccine is safe and effective to use. Canadian officials said they want more information about the blood clots, especially in young women. There have been no reports of blood clots in Canada, and the country is still using the vaccine for those over 55.
AstraZeneca's "vaccine has had all the ups and downs," Dr. Caroline Quach-Thanh, chair of the National Advisory Committee on Immunization, told reporters Monday. "It looks like a roller coaster." Canada approved the vaccine, developed by Oxford University, in late February, but only for people under 65. When British data came in showing its effectiveness on older people, Canada reversed itself. Now it has changed its advice again.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"The messaging has been brutal overall," Dr. Andrew Morris, a professor of infectious diseases at the University of Toronto, tells The Associated Press. "I am fearful it is toast. It shouldn't be."
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
US to take 15% cut of AI chip sales to China
Speed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with Disney
Speed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
-
Samsung to make Tesla chips in $16.5B deal
Speed Read Tesla has signed a deal to get its next-generation chips from Samsung
-
FCC greenlights $8B Paramount-Skydance merger
Speed Read The Federal Communications Commission will allow Paramount to merge with the Hollywood studio Skydance
-
Tesla reports plummeting profits
Speed Read The company may soon face more problems with the expiration of federal electric vehicle tax credits
-
Dollar faces historic slump as stocks hit new high
Speed Read While stocks have recovered post-Trump tariffs, the dollar has weakened more than 10% this year
-
Economists fear US inflation data less reliable
speed read The Labor Department is collecting less data for its consumer price index due to staffing shortages
-
Crypto firm Coinbase hacked, faces SEC scrutiny
Speed Read The Securities and Exchange Commission has also been investigating whether Coinbase misstated its user numbers in past disclosures